About us

Protein Technologies Ghent

Proteomics & biopharmaceutical protein production and delivery technologies


Protein Technologies Ghent is a consortium of research groups from UGent and VIB, each with a long-standing reputation of expertise in their respective fields.

Centered around facilitating biopharmaceutical moiety discovery and development, the consortium integrates the assembled know-how from its members to accelerate the process of developing novel therapies against e.g. viral infections, microbial antibiotics resistance and cancer.

These efforts inherently go hand-in-hand with the development of new supporting technologies.

The consortium aims to grant access to these high-end solutions for other public institutions and the biotech & pharma-industry in Belgium and beyond.

We do this by investing actively in the development of these assets into products that live up to industry-standards and subsequently offering integrated services to our network, or out-licensing the technology overall.

If deemed viable, we may choose to create a spin-off company in order to create the best circumstances for that particular technology to flourish.



Research topics include

  • Proteomics
  • Protein interaction studies
  • Recombinant (synthetic) protein production
  • Structural protein biology
  • Biopharmaceutical target discovery & therapeutic lead development
  • Nanodelivery technology


Protein Technologies is supported by UGent TechTransfer and Flemish Institute for Biotechnology (VIB).